Abhishek Krishna, MD
Pulmonary Disease · Canton, GANPI 1861725053
Payments from drug & device makers
Across 309 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Electromed, Inc.$712
- Grifols USA, LLC$679
- AstraZeneca$667
- Boehringer Ingelheim$489
- Sanofi$187
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,39399%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 67 | $1,152 |
| Electromed, Inc. | 72 | $712 |
| Grifols USA, LLC | 42 | $679 |
| AstraZeneca | 27 | $667 |
| Boehringer Ingelheim | 26 | $489 |
| Sanofi | 7 | $187 |
| Intuitive Surgical | 1 | $173 |
| Verona Pharma, Inc. | 8 | $143 |
| Regeneron Healthcare Solutions, Inc. | 6 | $124 |
| Insmed, Inc. | 5 | $113 |
| Actelion Pharmaceuticals US, Inc. | 3 | $78 |
| Mylan Specialty L.p. | 5 | $76 |
| Harmony Biosciences LLC | 2 | $70 |
| Philips North America LLC | 3 | $67 |
| Viatris Specialty LLC | 3 | $64 |
| Merck | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Vapotherm Inc | 2 | $51 |
| Tactile Systems Technology Inc | 1 | $43 |
| CSL Behring | 2 | $42 |
| Shire North American Group Inc | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $38 |
| Inogen, Inc. | 2 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $34 |
| Johnson & Johnson | 2 | $34 |
| Inari Medical, Inc. | 1 | $33 |
| Advanced Respiratory, Inc | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Amgen | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Pulmonx Corporation | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Resmed Corp | 1 | $15 |
| Galvanize Therapeutics, Inc | 1 | $15 |
| Apria Healthcare LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$173
- TRELEGY ELLIPTA$117
- FASENRA$112
How this compares
$5,451 in reported general payments places this provider in the 50th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 532 | $392,114 |
| ZemairaAlpha-1-Proteinase Inhibitor | 12 | $132,567 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 89 | $59,792 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $42,219 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $29,363 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $27,934 |
| EliquisApixaban | 11 | $8,516 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $8,343 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $6,819 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,722 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 186 | $4,316 |
| Roflumilast | 41 | $3,609 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,618 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $1,963 |
| Azelastine Hcl | 57 | $1,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,152 | $449,410651 claims |
| CSL BehringZemaira | $42 | $132,56712 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $489 | $65,514100 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $667 | $49,03887 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Canton
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.